Analysis of Efficacy and Prognostic Factors of Anlotinib for Patients with Advanced Gastric Cancer in the Real World
OBJECTIVE To observe the clinical efficacy and safety of Anlotinib hydrochloride capsules in pa-tients with advanced gastric cancer,and to find the clinical prognostic factors.METHODS Retrospective analysis was performed on 81 patients with advanced gastric cancer diagnosed histologically and treated in the Second Affilia-ted Hospital of Soochow University from June 2018 to June 2022.Relevant clinical information,treatment plan,clini-cal efficacy and safety were recorded,and prognostic factors were analyzed.RESULTS Among 81 patients with ad-vanced gastric cancer,0 patients had complete response(CR),6 patients had partial response(PR),30 patients had stable disease(SD),and the disease control rate(DCR)was 46.2％.Median progression-free survival(PFS)was 2.3 months(95％CI:1.5-3.1 months),and median overall survival(OS)was 4.4 months(95％CI:3.7-5.1 months).Univariate analysis showed significant differences in gender,surgery or not,drug regimen,liver metastases,D-dimer value,and Her2 status in stratified analyses of PFS and OS(P＜0.05).Multivariate Cox regression analy-sis,surgery and drug regimen are independent prognostic factors for advanced gastric cancer.The general adverse re-actions were fatigue,hand-foot-skin reaction,nausea,vomiting,abnormal thyroid function and hypertension,with the incidence of 48.1％(39/81),37.0％(30/81),29.6％(24/81),28.4％(23/81)and 18.5％(15/81),respective-ly,and no grade 4 adverse reactions occurred.CONCLUSION Compared with previous research data,anrotinib is better than traditional chemotherapy in the treatment of second-line and higher advanced gastric cancer,and patients are well tolerated.However,there is no advantage compared with apatinib and ramucirumab.Different drug regimens of antirotinib also had an effect on PFS and OS,among which antirotinib combined with chemotherapy was better,and antirotinib combined with immunization did not extend survival.
NETL
NSTL
万方数据
